Skip to main content
Premium Trial:

Request an Annual Quote

Asuragen: Aug 19, 2008

Premium
Asuragen this week launched Signature NPM1 Mutations, a multiplex, reverse-transcription PCR assay that enables the combined detection of mutations A, B, and D in exon 12 of the nucleophosmin (NPM1) gene.
 
According to Asuragen, the assay is designed to detect NPM1 mutant transcripts in total RNA isolated from cell line, whole blood, and bone marrow specimens. NPM1 has been reported to be one of the most commonly mutated genes in acute myeloid leukemia.
 

Signature NPM1 Mutations is made available on the Luminex 100 IS or 200 System using a liquid bead array method. According to the company, the liquid bead array format provides “comprehensive information in a single well, providing efficiency and cost benefits to the laboratory.”

The Scan

WHO Seeks Booster Pause

According to CNN, the World Health Organization is calling for a moratorium on administering SARS-CoV-2 vaccine boosters until more of the world has received initial doses.

For Those Long Legs

With its genome sequence and subsequent RNAi analyses, researchers have examined the genes that give long legs to daddy longlegs, New Scientist says.

September Plans

The New York Times reports that the US Food and Drug Administration is aiming for early September for full approval of the Pfizer-BioNTech SARS-CoV-2 vaccine.

Nucleic Acids Research Papers on Targeting DNA Damage Response, TSMiner, VarSAn

In Nucleic Acids Research this week: genetic changes affecting DNA damage response inhibitor response, "time-series miner" approach, and more.